NCT04066608Enrolling by invitation
Prevalence of Advanced Fibrosis in Patients Living With HIV
Cross-sectional Study on the Prevalence of Fatty Liver and Metabolic Risk Factors in an HIV-infected Population
Source: ClinicalTrials.gov · Last updated 28 Dec 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Monocentric, cross-sectional study to define the prevalence of advanced fibrosis in an HIV infected outpatient population. Follow-up over 10 years to assess clinical relevance.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 17 Aug 2019
- Start date
- 1 Oct 2018
- Primary completion date
- 1 Oct 2028
- Lead sponsor
- Johannes Gutenberg University Mainz
- Diseases
- HIV, Fatty liver disease (MASLD/MASH)
- NCT number
- NCT04066608
What you commit to
- Study type: Observational
- Planned participants: 300
- From 1 Oct 2018 to the primary completion date, 1 Oct 2028
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- disease with expectation of life under 12 months
Other
- pregnancy
Who the study is looking for
- informed consent
- age \>18
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Medical Center of the Johannes Gutenber Univeristy Coordinator of this site? Confirm its status | Mainz | Germany | Unknown status |
| University Medical Center of the Johannes Gutenberg University Coordinator of this site? Confirm its status | Mainz | Germany | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.